S. Bart

发表

Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study

V. Bockstal, Benoît Callendret, Auguste Gaddah, 2020, The Journal of infectious diseases.

A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant.

J. Falloon, M. Esser, F. Dubovsky, 2016, Vaccine.

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study

M. McElrath, S. D. De Rosa, M. Pau, 2022, PloS one.

A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever

J. Mekalanos, K. Killeen, R. Cartee, 2020, PLoS neglected tropical diseases.

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen

V. Bockstal, Auguste Gaddah, M. Douoguih, 2021, npj Vaccines.

Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.

A. Falsey, J. Sadoff, J. Menten, 2023, The New England journal of medicine.

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)

Galit Alter, David C Montefiori, Nigel Garrett, 2018, The Lancet.

A Cell Culture–Derived MF59-Adjuvanted Pandemic A/H7N9 Vaccine Is Immunogenic in Adults

P. Dormitzer, G. Della Cioppa, N. Kanesa-thasan, 2014, Science Translational Medicine.

Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, double-blind, active-controlled, parallel-group, US-based multicenter study.

K. Diefenbach, J. Marr, D. Trummer, 2012, Contraception.

Usability of daily SF36 questionnaires to capture the QALD variation experienced after vaccination with AS03A-adjuvanted monovalent influenza A (H5N1) vaccine in a safety and tolerability study

A. Madan, M. Kosinski, M. Hayney, 2019, Health and Quality of Life Outcomes.

A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults.

S. Weaver, C. Shaw, T. Brasel, 2023, Vaccine.

Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study

R. Mills, E. Forleo-Neto, K. Lindert, 2016, Human vaccines & immunotherapeutics.

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen

V. Bockstal, Auguste Gaddah, M. Douoguih, 2021, NPJ vaccines.

Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults

C. Truyers, M. Douoguih, N. Goldstein, 2016 .